Interim
Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy
Rentschler Biopharma; Executive Board Changes; Interim CEO; Corporate Strategy; Uwe Buecheler; Benedikt von Braunmuehl; Christiane Bardroff
Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment
Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression
Amylyx Reveals Interim Rare Disease Data for Withdrawn ALS Therapy
Amylyx, Rare disease data, ALS drug withdrawal, Interim results, Rare neurological disorder